Abbott Laboratories Past Earnings Performance
Past criteria checks 4/6
Abbott Laboratories has been growing earnings at an average annual rate of 8.9%, while the Medical Equipment industry saw earnings growing at 12% annually. Revenues have been growing at an average rate of 5.5% per year. Abbott Laboratories's return on equity is 14.4%, and it has net margins of 13.9%.
Key information
8.9%
Earnings growth rate
9.3%
EPS growth rate
Medical Equipment Industry Growth | 8.9% |
Revenue growth rate | 5.5% |
Return on equity | 14.4% |
Net Margin | 13.9% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Calculating The Fair Value Of Abbott Laboratories (NYSE:ABT)
Dec 01Abbott Laboratories: Investors Should Wait For A Pullback
Nov 25Investors Will Want Abbott Laboratories' (NYSE:ABT) Growth In ROCE To Persist
Oct 31Abbott Laboratories: Long-Term Optimism, Short-Term Overvaluation
Oct 21Abbott: Challenging Comparables, Unappealing Value Limit The Incentive To Go Long Ahead Of Q3 Event
Oct 14Does Abbott Laboratories (NYSE:ABT) Have A Healthy Balance Sheet?
Oct 11Why We're Not Concerned About Abbott Laboratories' (NYSE:ABT) Share Price
Sep 27Abbott Laboratories: Cardiovascular Disease Has Been A Tailwind, But Things Could Change
Sep 11A Look At The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)
Aug 16Abbott Laboratories: Driving Value By Scaling Innovations
Aug 13Abbott Laboratories: A Strong Healthcare Stock For Long-Term Dividend Growth Investors
Aug 05Abbott Laboratories: When Double-Digit Device Growth Apparently Isn't Enough
Jul 13These 4 Measures Indicate That Abbott Laboratories (NYSE:ABT) Is Using Debt Reasonably Well
Jul 01Abbott Laboratories (NYSE:ABT) Is Doing The Right Things To Multiply Its Share Price
Jun 18Investors Still Waiting For A Pull Back In Abbott Laboratories (NYSE:ABT)
Jun 04Abbott Laboratories: Why I Agree With Wall Street On This One
Jun 04Abbott Laboratories: Buying More Of This Top-Notch Dividend Growth Stock
May 18Abbott Laboratories: Organic Growth Will Be Key To Q1 Earnings
Apr 17Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)
Apr 15Abbott Laboratories: Buy This World-Class Dividend Growth Stock Now
Mar 21Abbott Laboratories (NYSE:ABT) Might Have The Makings Of A Multi-Bagger
Mar 19Here's Why Abbott Laboratories (NYSE:ABT) Can Manage Its Debt Responsibly
Mar 06Abbott Labs' Reversal Is Here - CGM Tailwinds In 2024
Feb 27Abbott Laboratories' (NYSE:ABT) Shares May Have Run Too Fast Too Soon
Feb 08Revenue & Expenses Breakdown
How Abbott Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 41,217 | 5,744 | 10,902 | 2,646 |
30 Jun 24 | 40,725 | 5,535 | 10,743 | 2,605 |
31 Mar 24 | 40,326 | 5,608 | 10,565 | 2,648 |
31 Dec 23 | 40,109 | 5,701 | 10,385 | 2,619 |
30 Sep 23 | 39,959 | 5,142 | 10,583 | 2,619 |
30 Jun 23 | 40,226 | 5,140 | 10,611 | 2,729 |
31 Mar 23 | 41,505 | 5,785 | 10,657 | 2,698 |
31 Dec 22 | 43,653 | 6,905 | 10,703 | 2,741 |
30 Sep 22 | 45,030 | 7,857 | 10,901 | 2,921 |
30 Jun 22 | 45,548 | 8,520 | 10,971 | 2,811 |
31 Mar 22 | 44,514 | 7,695 | 10,978 | 2,781 |
31 Dec 21 | 43,075 | 7,042 | 11,006 | 2,738 |
30 Sep 21 | 42,308 | 7,208 | 10,593 | 2,623 |
30 Jun 21 | 40,233 | 6,343 | 10,244 | 2,531 |
31 Mar 21 | 37,338 | 5,693 | 9,807 | 2,441 |
31 Dec 20 | 34,608 | 4,449 | 9,591 | 2,420 |
30 Sep 20 | 32,221 | 3,346 | 9,405 | 2,289 |
30 Jun 20 | 31,444 | 3,073 | 9,440 | 2,305 |
31 Mar 20 | 32,095 | 3,539 | 9,597 | 2,318 |
31 Dec 19 | 31,904 | 3,666 | 9,540 | 2,440 |
30 Sep 19 | 31,355 | 3,272 | 9,452 | 2,395 |
30 Jun 19 | 30,935 | 2,867 | 9,403 | 2,373 |
31 Mar 19 | 30,723 | 2,582 | 9,448 | 2,371 |
31 Dec 18 | 30,578 | 2,319 | 9,568 | 2,298 |
30 Sep 18 | 30,402 | 802 | 9,482 | 2,280 |
30 Jun 18 | 29,575 | 812 | 9,141 | 2,274 |
31 Mar 18 | 28,445 | 365 | 8,868 | 2,219 |
31 Dec 17 | 27,390 | 344 | 8,804 | 2,183 |
30 Sep 17 | 25,134 | 1,971 | 8,175 | 1,979 |
30 Jun 17 | 23,607 | 1,055 | 7,808 | 1,763 |
31 Mar 17 | 22,303 | 1,384 | 7,395 | 1,575 |
31 Dec 16 | 20,853 | 1,056 | 6,558 | 1,442 |
30 Sep 16 | 20,708 | 989 | 6,620 | 1,353 |
30 Jun 16 | 20,556 | 1,939 | 6,658 | 1,379 |
31 Mar 16 | 20,393 | 2,124 | 6,648 | 1,392 |
31 Dec 15 | 20,405 | 2,586 | 6,742 | 1,371 |
30 Sep 15 | 20,573 | 2,523 | 6,593 | 1,338 |
30 Jun 15 | 20,502 | 2,365 | 6,522 | 1,265 |
31 Mar 15 | 20,389 | 2,004 | 6,444 | 1,230 |
31 Dec 14 | 20,247 | 1,710 | 6,327 | 1,286 |
30 Sep 14 | 19,905 | 1,560 | 6,373 | 1,343 |
30 Jun 14 | 19,651 | 1,762 | 6,390 | 1,377 |
31 Mar 14 | 19,034 | 1,654 | 6,174 | 1,394 |
31 Dec 13 | 19,657 | 1,970 | 6,340 | 1,371 |
Quality Earnings: ABT has high quality earnings.
Growing Profit Margin: ABT's current net profit margins (13.9%) are higher than last year (12.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ABT's earnings have grown by 8.9% per year over the past 5 years.
Accelerating Growth: ABT's earnings growth over the past year (11.7%) exceeds its 5-year average (8.9% per year).
Earnings vs Industry: ABT earnings growth over the past year (11.7%) did not outperform the Medical Equipment industry 12.9%.
Return on Equity
High ROE: ABT's Return on Equity (14.4%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/19 05:45 |
End of Day Share Price | 2024/12/19 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Abbott Laboratories is covered by 61 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
David Toung | Argus Research Company |
Stephan Gasteyger | Atlantic Equities LLP |
Ishan Majumdar | Baptista Research |